Cetuximab
About
Therapy type: Targeted therapy
Therapy strategy: EGFR inhibition
Mappings
NCI Thesaurus: Cetuximab (ncit:C1723)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) HC (1) | EGFR positive, Wild type KRAS | Colorectal Adenocarcinoma | Cetuximab, Fluorouracil, Irinotecan | |
| FDA (1) HC (1) | EGFR positive, Wild type KRAS | Colorectal Adenocarcinoma | Cetuximab, Irinotecan | |
| FDA (1) HC (2) | EGFR positive, Wild type KRAS | Colorectal Adenocarcinoma | Cetuximab | |
| FDA (2) HC (1) | BRAF p.V600E | Colorectal Adenocarcinoma | Cetuximab, Encorafenib | |
| FDA (1) | KRAS p.G12C | Colorectal Adenocarcinoma | Adagrasib, Cetuximab | |
| FDA (1) | BRAF p.V600E | Colorectal Adenocarcinoma | Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin |